Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

Biosimilars Market Competitive Landscape

Pfizer Inc. is one of the leading pharmaceutical companies that discovers, manufactures, and develops healthcare products, including innovative vaccines and medicines. The company aims to advance prevention, wellness, cures, and treatments for challenging critical diseases. In 2021, the company’s medicines and vaccines were used by approximately 1.4 billion people. Moreover, it initiated 13 clinical studies in 2021.

 

Celltrion Inc. is a pharmaceutical company based in Korea that introduced the "antibody biosimilar". It has broken ground in a number of previously unexplored areas, and it aims to expand as a global biopharmaceutical company. With sales in more than 90 countries and a production capacity of 190,000 litres, the company has a workforce of 2145 and revenue of USD 153 billion. Moreover, it is significantly boosting R&D activities to increase the biosimilars market demand.

 

Novartis AG is a pharmaceutical company that aims to extend and improve people’s lives by reimaging medicine. Its products are utilised by about 800 million people across the globe. With more than 108,000 employees, the company aims to deliver and discover new treatments and therapies. Its leading companies include Sandoz, Gyroscope Therapeutics, and Advanced Accelerator Applications.

 

AMGen Inc. is one of the major biotechnology companies. It focuses on areas with large unmet medical needs and uses its expertise to develop solutions offering improved health outcomes. It operates in over 100 countries in the world, and its breakthrough medications have helped millions of people combat critical illnesses.

 

Teva Pharmaceutical Industries Ltd. is a major generic drug and biopharmaceutical company. It is also a global leader in active pharmaceutical ingredients and speciality pharmaceuticals. The company has a presence in more than 60 markets globally and has a portfolio of approximately 3,000 medicines. With over 55 manufacturing facilities in more than 30 countries, the company serves nearly 200 million people every day.

 

Samsung Bioepis is a biopharmaceutical company that is focused on maximising the value of biosimilar products and medicines. It also aims to revolutionise the delivery of biologic therapeutics to patients as well as the biosimilars market. It employs more than 900 employees and oncology, immunology, ophthalmology, haematology, gastroenterology, and endocrinology are among the six major therapeutic areas of the company.

 

Biocon Ltd. is a global pharmaceutical company with a widespread presence all over the globe in over 120 countries. It is a pioneer in defining affordable and innovative approaches to treat diabetes, cancer, and autoimmune diseases. It has four major lines of business - biosimilars, generics, novel biologics, and research services, and employs over 12,000 people across the globe.

 

Biosimilars Market Report Snapshots

Biosimilars Market Size

Biosimilars Market Analysis

Biosimilars Market Growth

Biosimilars Companies

Biosimilars Market Regional Analysis

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global biosimilar market was valued at USD 24.5 billion in 2024.

The market is expected to grow at a CAGR of 17.60% from 2025 to 2034 to reach a value of USD 105.1 billion by 2034.

Biosimilars are likely to enhance innovations in the healthcare sector and increase the development of innovative drugs. Further, by boosting competitiveness between the key players, they are expected to enhance the accessibility to critical biologics and lower healthcare costs.

Biosimilars are made from biologic sources whereas generic drugs use chemicals as their primary sources. Moreover, biosimilars require special approval to be considered interchangeable while generic drugs are automatically interchangeable with biologics.

The market is being aided by the growing prevalence of various chronic diseases, the rising use of biosimilars in cancer treatment, and the increasing demand for cost-effective treatment methods.

The global biosimilars market is estimated to grow at a CAGR of 18.1% between 2025 and 2034.

The market is anticipated to be supported by the increasing research and development (R&D) activities, the surging approvals of biosimilars, and the growing introduction of new biosimilars.

Some of the major benefits of biosimilars include enhanced cost-effectiveness and efficacy of critical biologics. They also enable the reallocation of resources to other patient care requirements by providing affordable treatment options and improving treatment outcomes.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major molecules of biosimilars in the market are infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa.

The significant manufacturing segments in the market include contract and in-house manufacturing.

The various indications in the market for biosimilars are auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility.

The major players in the market are Pfizer Inc., Celltrion Inc., Novartis AG, AMGen Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis, and Biocon Ltd., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

$getforecastarray = array(); if (isset($ismapshow)) { $forecast_period_start = isset($forecast_period_start) ? $forecast_period_start : ''; if ($forecast_period_start != "") { $yearInc = 1; for ($startfrom = $forecast_period_start; $startfrom <= $forecast_period_end; $startfrom++) { $calculatFercastYear=calculateFutureValue(($getReportDetail['base_value']> 0) ? $getReportDetail['base_value'] : 100, $getReportDetail['cagr'], $yearInc); $getforecastarray[] = array('years' => "$startfrom", 'value' => $calculatFercastYear); $yearInc++; } } } $getforecastarrayJson = json_encode($getforecastarray); ?>